- Home
- IMNM vs MNKD Comparison
IMNM vs MNKD Comparison
Compare IMNM & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | MNKD |
|---|---|---|
| Founded | 2006 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2020 | 2004 |
Fundamental Metrics
Financial Performance| Metric | IMNM | MNKD |
|---|---|---|
| Price | $21.77 | $5.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $31.44 | $10.08 |
| AVG Volume (30 Days) | 2.9M | ★ 3.4M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | N/A | ★ 0.10 |
| Revenue | $9,679,000.00 | ★ $313,787,000.00 |
| Revenue This Year | N/A | $21.54 |
| Revenue Next Year | $11.53 | $22.21 |
| P/E Ratio | ★ N/A | $59.15 |
| Revenue Growth | N/A | ★ 17.43 |
| 52 Week Low | $5.15 | $3.38 |
| 52 Week High | $25.30 | $6.90 |
Technical Indicators
Market Signals| Indicator | IMNM | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 54.07 |
| Support Level | $19.37 | $5.59 |
| Resistance Level | $22.57 | $6.12 |
| Average True Range (ATR) | 1.48 | 0.19 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 45.30 | 37.84 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.